Breaking News, Collaborations & Alliances

OctoPlus, Axentis in Service Pact

OctoPlus has signed a development and manufacturing contract with Axentis Pharma

OctoPlus N.V. has signed a pharmaceutical development and manufacturing contract with a new client, Axentis Pharma AG. OctoPlus will perform process development and clinical manufacturing of Axentis’ lead product, an inhalable liposomal formulation of tobramycin for the treatment of cystic fibrosis. Terms of the contract were not disclosed.

OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide, as well as drug delivery technologies for the development of controlled release versions of existing or new drugs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters